Therefore, our first hypothesis was that CYP2D6/CYP2C19 PM and IM patients, in addition to CYP2C19 UM patients, would show higher rates of switching and/or discontinuing AD treatment over time than CYP2D6/CYP2C19 NM patients. This evidence concerns the gene CYP2C19 and Alzheimer disease.